Last reviewed · How we verify
NCT01377532
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
trial testing 131 I-Metaiodobenzylguanidine (131 I-MIBG) in Pheochromocytoma. Approved for marketing.
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- 131 I-Metaiodobenzylguanidine (131 I-MIBG) — full drug profile →
Conditions studied
- Pheochromocytoma — all drugs for Pheochromocytoma →
- Paraganglioma — all drugs for Paraganglioma →
Sponsor
University of California, San Francisco
Who can join
2 and older, any sex, with Pheochromocytoma or Paraganglioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM, Nazari MA, Jha A, Pacak K. · · 2022 · cited 19× · PMID 35903274 · DOI 10.3389/fendo.2022.936178
Verify or expand the search:
- PubMed search for NCT01377532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 131 I-Metaiodobenzylguanidine (131 I-MIBG)
Trials testing the same drug.
- NCT01163383 — 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol · available
Other recruiting trials for Pheochromocytoma
Currently open trials in the same condition.
- NCT06427798 — Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc · Phase 1, PHASE2 · recruiting
- NCT07195500 — Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting
- NCT06444607 — Hereditary Pheochromocytoma Assessment of Tumour Immunologies · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01377532 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 6 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01377532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing